Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort

Esther Molina-Montes, María José Sánchez, Raul Zamora-Ros, H. Bas Bueno-de-Mesquita, Petra A. Wark, Mireia Obon-Santacana, Tilman Kühn, Verena Katzke, Ruth C. Travis, Weimin Ye, Malin Sund, Alessio Naccarati, Amalia Mattiello, Vittorio Krogh, Caterina Martorana, Giovanna Masala, Pilar Amiano, José María Huerta, Aurelio Barricarte, José Ramón QuirósElisabete Weiderpass, Lene Angell Åsli, Guri Skeie, Ulrika Ericson, Emily Sonestedt, Petra H. Peeters, Isabelle Romieu, Augustin Scalbert, Kim Overvad, Matthias Clemens, Heiner Boeing, Antonia Trichopoulou, Eleni Peppa, Pavlos Vidalis, Kay Tee Khaw, Nick Wareham, Anja Olsen, Anne Tjønneland, Marie Christine Boutroun-Rualt, Françoise Clavel-Chapelon, Amanda J. Cross, Yunxia Lu, Elio Riboli, Eric J. Duell

    Research output: Contribution to journalArticlepeer-review

    18 Citations (Scopus)
    37 Downloads (Pure)


    Despite the potential cancer preventive effects of flavonoids and lignans, their ability to reduce pancreatic cancer risk has not been demonstrated in epidemiological studies. Our aim was to examine the association between dietary intakes of flavonoids and lignans and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 865 exocrine pancreatic cancer cases occurred after 11.3 years of follow-up of 477,309 cohort members. Dietary flavonoid and lignan intake was estimated through validated dietary questionnaires and the US Department of Agriculture (USDA) and Phenol Explorer databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated using age, sex and center-stratified Cox proportional hazards models, adjusted for energy intake, body mass index (BMI), smoking, alcohol and diabetes status. Our results showed that neither overall dietary intake of flavonoids nor of lignans were associated with pancreatic cancer risk (multivariable-adjusted HR for a doubling of intake = 1.03, 95% CI: 0.95–1.11 and 1.02; 95% CI: 0.89–1.17, respectively). Statistically significant associations were also not observed by flavonoid subclasses. An inverse association between intake of flavanones and pancreatic cancer risk was apparent, without reaching statistical significance, in microscopically confirmed cases (HR for a doubling of intake = 0.96, 95% CI: 0.91–1.00). In conclusion, we did not observe an association between intake of flavonoids, flavonoid subclasses or lignans and pancreatic cancer risk in the EPIC cohort.

    Original languageEnglish
    Pages (from-to)1480-1492
    Number of pages13
    JournalInternational Journal of Cancer
    Issue number7
    Early online date17 May 2016
    Publication statusPublished - 1 Oct 2016


    • cohort
    • diet
    • flavonoids
    • lignans
    • pancreatic cancer

    ASJC Scopus subject areas

    • Medicine(all)
    • Oncology
    • Cancer Research


    Dive into the research topics of 'Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort'. Together they form a unique fingerprint.

    Cite this